About this Research Topic
Most EVE are not able to replicate and form virus particles autonomously. In addition to genetic inactivation, epigenetic control of EVE transcription plays an important role for EVE regulation. Epigenetic mechanisms are reversible and, therefore, reactivation of EVE can occur under physiological and pathological conditions. Such reactivation cannot only affect EVE with complete open reading frames but also EVE with disrupted genomes that are not encoding functionally intact proteins.
Activation of EVE loci can have varying consequences for the host. Some EVE proteins (syncytins, supressyn) are involved in cell-cell fusion events, e.g. during placenta development. Other EVE proteins can act as (super-)antigens and can activate the immune system. In addition, reactivated EVE loci can induce or repress expression of adjacent genes. Finally, EVE are a major source for short and long non-coding RNA as well as double-stranded DNA with potential functions for gene regulation and innate immunity.
Increased EVE transcription has been observed in certain cancer types as well as autoimmune diseases. In some of these cases, release of EVE-derived virus particles from cells has been observed. Reactivation of EVE under such diverse conditions might indicate common pathways in cancer and autoimmunity.
This Research Topic is calling for submission of original research papers and review articles about all aspects of EVE reactivation in the context of cancer and autoimmune diseases.
Keywords: Endogenous Viral Elements (EVE), Endogenous Retroviruses (ERV), Cancer, Autoimmunity
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.